Mesoscale Technologies, Llc.

Igen International, Inc.

Igen, Inc.

Bioveris Corporation

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Other

Wellstat Biocatalysis, LLC

Proteinix Corporation

Proteinix Company

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Eisai Company, Limited

Pro-neuron, Inc.

Proteinex, Inc.

Igen Inaternational, Inc.

John H Kenten

Eli N Glezer

Richard J Massey

George B Sigal

Jack E Goodman

Gary F Blackburn

Haresh P Shah

George E Lowke

Yuzaburo Namba

Martin Stengelin

Anahit Aghvanyan

Steven F Roberts

Hans Biebuyck

Rodger G Smith

Jonathan K Leland

Sudeep Kumar

Ilia V Davydov

John K Leland

Richard O Williams

Satyanarayana R Gudibande

Mark T Martin

Michael Joseph Powell

Pankaj Oberoi

Aprile L Pilon

Richard C Titmas

David M Simpson

Anu Mathew

Natalia I Ossetrova

William F Blakely

David Routenberg

Jan M Casadei

Alfonso Tramontano

Gerald L Lohnas

Jacob N Wohlstadter

Reid W Von Borstel

Niranjan Y Sardesai

James L Wilbur

Jeff D Debad

Michael Tsionsky

Kent Johnson

Sudhir Paul

Balreddy Kamireddy

Robert M Umek

Jeffrey A Heroux

Andrew D Napper

Paula Denney Eason

Douglas Woods

Maura C Kibbey

John R Link

Galina Nikolenko

John Gerald McCafferty

David John Chiswell

Michael J Darsley

Allan M Weissman

Yili Yang

Jane P Jensen

Shengyun Fang

Yassamin J Safiran

Nisar Pampori

Steven Yan Cheng

Stefanie Nelson

Kevin Fitzgerald

Karen H Vousden

Srikant Vaithilingam

Stefani Nelson

The present invention is directed to methods for improving assay specificity and performance in binding assays.

Assay methods

The present invention relates to methods of diagnosing glomerulonephritis (GN) in a patient, as well as methods of monitoring the progression of GN and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Glomerulonephritis biomarkers

Methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. Also, algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

Biodosimetry panels and methods

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Lung cancer biomarkers

The present invention is directed to improved methods for conducting immunoassays. The methods are designed to amplify signals in immunoassays and anchor immunoassay complexes employed therein.

Method of detecting analyte in a sample with binding reagent, first detection reagent, and second detection reagent

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

The present invention is directed to kits for improving assay specificity and performance in binding assays.

Assay kits

The present disclosure is directed to a kit for the detection of an analyte of interest in a sample comprising, in one or more vials, containers, or compartments, a. a surface comprising (i) a capture reagent for the analyte, said capture reagent bound to the surface, and (ii) an anchoring reagent bound to an anchoring oligonucleotide sequence, said anchoring reagent bound to the surface, b. a first detection reagent for the analyte that is linked to a first nucleic acid probe, wherein the first nucleic acid probe comprises an extended sequence that is complementary to the anchoring oligonucleotide sequence and c. a second detection reagent for the analyte that is linked to a second nucleic acid probe.

The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.

Multiplexed test measurements are conducted using an assay module having a plurality of assay domains. In preferred embodiments, these measurements are conducted in assay modules having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence.

Methods and apparatus for conducting multiple measurements on a sample

The present invention relates to methods, compositions, compounds and kits for detecting, measuring and modulating protein ubiquitylation via the N-end rule pathway and for identifying novel substrates, enzymes and modulators of N-end rule ubiquitylation. The present invention also relates to specific substrates of N-end rule ubiquitylation as well as activated fragments of these substrates, proteases that expose N-degrons in these substrates, ubiquitin ligases that ubiquitylate these substrates and inhibitors of the ubiquitylation of these substrates.

Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrate

Growing community of inventors

Gaithersburg, MD, United States of America

John H Kenten